Skip to content
Demo
Creator Hubs›Crown Bioscience

Crown Bioscience

Crown Bioscience logo

News, updates, and expert insights from Crown Bioscience.

Crown Bioscience is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to deliver integrated preclinical and translational research solutions, supporting programs from target discovery through clinical development.

4 episodesVisit website ↗
Channel Brief·Crown Bioscience · 4 episodes
Updated Sep 30, 2026

Preclinical model design determines oncology therapy success

Crown Bioscience argues that cancer drug efficacy depends on building preclinical models that match the therapy's mechanism and delivery route, not the reverse. The channel supports this with examples of orthotopic implantation, PDX design, and biomarker integration.

Crown Bioscience's core argument is that preclinical oncology models must be engineered to fit the specific therapy being tested, including its delivery route, surgical approach, and target organ. The channel demonstrates this principle through examples like orthotopic brain tumor implantation at Crown's San Diego site, where tumors are implanted directly in the brain and treated in that location to match clinical intent, rather than using convenient subcutaneous models.

Drawn from Crown Bioscience's San Diego site fits the tum… →

“A preclinical model should fit the therapy being tested, including its delivery route, the surgery it needs and the organ it targets.”

Crown Bioscience's San Diego site

By the numbers

300+

new cancer therapies FDA-approved in last two decades

$230B+

global pharmaceutical R&D spending projected by 2026

What the channel argues

InsightOrthotopic brain tumor implantation lets researchers track growth in the original organ and test therapies via intended delivery route.→
InsightPost-treatment PDX models better reflect progressed disease for studying therapies in patients whose cancer has advanced after earlier treatment.→
InsightBiomarker analysis at a single site combining preclinical model samples with clinical testing improves animal-to-patient translation.→
DataOver 300 FDA-approved cancer therapies in two decades have not solved the resistance problem, with cancer cells adapting to evade even advanced therapeutics.→
DataAI can cut drug development timelines by nearly half while improving accuracy in identifying promising compounds.→
InsightCombination therapies and emerging cell-based treatments including TIL therapies, bispecific antibodies, and CAR-T technologies are reshaping immuno-oncology approaches.→

What you'll learn

•Preclinical model design must prioritize alignment with clinical delivery route and organ of interest rather than experimental convenience.
•Post-treatment patient-derived xenografts capture disease progression dynamics relevant to therapies targeting relapsed or resistant cancers.
•Cancer cell resistance remains a persistent challenge despite three decades of innovation in approved therapies and mechanisms.
•AI-enabled drug discovery can halve development timelines by improving compound identification accuracy early in the pipeline.
•Immuno-oncology advances in CAR-T, TIL, and bispecific antibody technologies now require combination strategies to overcome tumor microenvironment challenges.

What to do about it

→Audit your preclinical model selection against the intended clinical delivery route and target organ of your therapy candidate.
→Integrate biomarker analysis across both preclinical model and planned clinical testing at your CRO to establish translational confidence early.
→Evaluate AI-driven drug discovery platforms for lead identification and optimization to compress timeline pressure in your pipeline.

Who and what shows up

Crown Bioscience

Contract research organization, oncology preclinical models

Operates San Diego site designing orthotopic tumor models and post-treatment PDX to match specific therapies and enable biomarker-linked translational studies.

Questions this channel answers

Q

Why does preclinical model choice matter more than model type?

The model must align with the therapy's delivery route, surgical approach, and target organ to predict clinical performance. Subcutaneous convenience does not reflect orthotopic implant efficacy or intravenous delivery dynamics.

Crown Bioscience's San Diego site fits the tumor model t… →
Q

How do you design a preclinical model for patients whose cancer has already progressed?

Post-treatment patient-derived xenografts developed from tumors after prior treatment reflect advanced or resistant disease better than naive primary tumors, enabling study of therapies aimed at progression.

Crown Bioscience's San Diego site fits the tumor model t… →
Q

Why is cancer cell resistance still a major problem despite hundreds of new therapies?

Cancer cells evolve and adapt to evade even cutting-edge therapeutics, and resistance often leads to disease relapse and poor patient outcomes. New technologies like CRISPR, multi-omics, and organoids are being deployed to understand resistance pathways.

Inside Oncology Drug Development: Overcoming Resistance … →
Q

What is the role of combination therapy in immuno-oncology?

Combination therapies are crucial for overcoming immune resistance and addressing challenges posed by the tumor microenvironment and immune cell exhaustion to increase therapeutic success rates.

Shaping the Future of Cancer Care Through Immuno-Oncolog… →
Q

How does AI impact oncology drug development speed and accuracy?

AI slashes drug development time by nearly half while improving accuracy in identifying promising compounds, addressing the pressure of rising R&D costs and long development cycles.

Exploring Artificial Intelligence in Drug Discovery →
Topics:Orthotopic tumor modelsPatient-derived xenografts (PDX)Drug resistance mechanismsImmuno-oncology combinationsAI-driven drug discovery
Themes:Model-therapy fit over convenienceTranslational biomarker continuityResistance as a design problem

Industry context

Oncology precision medicine approaches—combining biomarker-driven diagnostics with targeted therapeutics—are projected to reach $226.55 billion by 2030, with CAR-T, gene therapies, and AI-enhanced clinical decision-making driving growth.

Want a show like this for your brand?

MarketScale produces and distributes branded shows like Crown Bioscience for B2B companies.

Book a Demo →